Home > News & Events > News Corporate
January 2020
 
Chiesi Group and Apotex Inc. finalize agreement for acquisition of Ferriprox® (deferiprone)
13/01/2020
 
August 2019
 
Chiesi Group Announces Closing of Licensing Transaction with Santhera for an orphan drug in LHON
02/08/2019
 
May 2019
 
Chiesi Group Enters into License Agreement with Santhera for a treatment for LHON
23/05/2019
 
Chiesi Group signs an Option Agreement with Inhibrx for Development and Commercialization of...
30/05/2019
 
February 2019
 
Chiesi Farmaceutici changes statute to become “Benefit Corporation”.
04/02/2019
 
October 2018
 
StartUp Health raises 31 million dollars from the Chiesi Group and a prominent group of other large...
02/10/2018
 
September 2018
 
Chiesi Acquires NHCO Nutrition® SAS and strengthens its OTC portfolio in France.
03/09/2018
 
July 2018
 
Protalix BioTherapeutics Expands Partnership with Chiesi Farmaceutici to Include Exclusive U.S....
24/07/2018
 
June 2018
 
Chiesi signs a deal with StartUp Health: first investment in the digital area
05/06/2018
 
March 2018
 
Global Corporate Development : opening of new offices in Boston
16/03/2018
 
October 2017
 
Chiesi enters into an Exclusive ex-US Partnership with Protalix BioTherapeutics for the Development...
20/10/2017
 
June 2017
 
Chiesi Farmaceutici completes the acquisition of European Marketing Rights
23/06/2017
 
November 2016
 
Chiesi Enhances Asthma Portfolio with Acquisition of Atopix Therapeutics
21/11/2016
Parma
 
May 2016
 
Chiesi To Acquire 3 Hospital Products
10/05/2016
 
October 2013
 
PERSISTENT ASTHMA: THE INNOVATIVE INHALER AVIALABLE IN ITALY
09/10/2013